Skip to main navigation Skip to search Skip to main content

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

  • Sungkyunkwan University
  • Duke University

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science